Literature DB >> 19897252

Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach.

Ilya A Lipkovich1, Walter Deberdt, John G Csernansky, Peter Buckley, Joseph Peuskens, Sara Kollack-Walker, Matthew Rotelli, John P Houston.   

Abstract

The study's goal was to characterize the typology of patient outcomes based on social and occupational functioning and psychiatric symptoms following antipsychotic drug treatment, and to explore predictors of group membership representing the best/worst outcomes. A hierarchical cluster analysis was used to define groups of patients (n=1449) based on endpoint values for psychiatric symptoms, social functioning, and useful work measured up to 30 weeks of treatment. Stepwise logistic regression was used to construct predictive models of cluster membership for baseline predictors, and with 2/4/8 weeks of treatment. Five distinct clusters of patients were identified at endpoint (Clusters A-E). Patients in Cluster A (25.6%, best outcome) had minimal psychiatric symptoms and mild functional impairment, while patients in Cluster D (14.3%) and E (14.8%) (worst outcome) had moderate-to-severe symptoms and severe functional impairment. Occupational functioning, disorganized thinking, and positive symptoms were sufficient to describe the clusters. Membership in the best/worst clusters was predicted by baseline scores for functioning and symptom severity, and by early changes in symptoms with treatment. Psychiatric symptoms and functioning provided complementary information to describe treatment outcomes. Early symptom response significantly improved the prediction of outcome, suggesting that early monitoring of treatment response may be useful in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897252     DOI: 10.1016/j.psychres.2008.09.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

1.  How to interpret multidimensional quality of life questionnaires for patients with schizophrenia?

Authors:  Pierre Michel; Pascal Auquier; Karine Baumstarck; Anderson Loundou; Badih Ghattas; Christophe Lançon; Laurent Boyer
Journal:  Qual Life Res       Date:  2015-04-09       Impact factor: 4.147

2.  Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods.

Authors:  Rebecca Schennach; Hans-Jürgen Möller; Michael Obermeier; Florian Seemüller; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Richard Musil; Ilja Spellmann; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2015-07-14       Impact factor: 4.035

3.  Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.

Authors:  Mark S Ezeme; Richard Uwakwe; Appolos C Ndukuba; Monday N Igwe; Paul C Odinka; Kennedy Amadi; Nichodemus O Obayi
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

Review 4.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

5.  Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis.

Authors:  Joseph Peuskens; Vibeke Porsdal; Jan Pecenak; Peter Handest; Yulia D'yachkova; Radim Brousil; Walter Deberdt
Journal:  BMC Psychiatry       Date:  2012-08-31       Impact factor: 3.630

6.  The heterogeneity of antipsychotic response in the treatment of schizophrenia.

Authors:  M Case; V L Stauffer; H Ascher-Svanum; R Conley; S Kapur; J M Kane; S Kollack-Walker; J Jacob; B J Kinon
Journal:  Psychol Med       Date:  2010-10-07       Impact factor: 7.723

7.  Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study.

Authors:  Gebra B Cuyún Carter; Denái R Milton; Haya Ascher-Svanum; Douglas E Faries
Journal:  BMC Psychiatry       Date:  2011-08-26       Impact factor: 3.630

8.  Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jaume Aguado; Zhanglin Cui
Journal:  Qual Life Res       Date:  2012-12-14       Impact factor: 4.147

9.  The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia.

Authors:  Ryoko Nakagawa; Takashi Ohnishi; Hisanori Kobayashi; Akihide Wakamatsu; Ai Tanimura; Kazuo Morita; Toshio Yamaoka; Hideo Usui; Yoshimasa Ogawa; Akiko Fujino; Kazutake Yoshizawa
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-22       Impact factor: 2.570

10.  Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.

Authors:  Wenyu Ye; William Montgomery; Zbigniew Kadziola; Li Liu; Haibo Xue; Michael D Stensland; Tamas Treuer
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.